Open Access

TRIM22 inhibits endometrial cancer progression through the NOD2/NF‑κB signaling pathway and confers a favorable prognosis

  • Authors:
    • Liping Zhang
    • Bingqian Zhang
    • Muyun Wei
    • Zhen Xu
    • Weiya Kong
    • Ke Deng
    • Xinxin Xu
    • Lin Zhang
    • Xingbo Ζhao
    • Lei Yan
  • View Affiliations

  • Published online on: March 4, 2020     https://doi.org/10.3892/ijo.2020.5004
  • Pages: 1225-1239
  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Endometrial cancer (EnC) is a malignant gynecological tumor commonly observed in developed countries, specifically among post‑menopausal women. Although numerous patients with EnC receive promising prognoses, those with advanced or metastatic disease often have a poor prognosis and an impaired quality of life. Tripartite motif‑containing 22 (TRIM22) has been confirmed to play many crucial roles in different biological processes, from inflammatory to tumorigenesis. However, the multifaceted roles of TRIM22 in EnC remain uncharacterized. Herein, comparing normal endometrial tissues with tumor tissues obtained from patients, it was concluded that TRIM22 expression was decreased in tumor tissues. However, the overexpression of TRIM22 served to inhibit the migratory, invasive, proliferative and cell cycle activity of EnC cells. Moreover, the knockdown of TRIM22 increased the migratory, invasive, and proliferative activity of the EnC cells. Furthermore, it was found that TRIM22 effectively suppressed EnC progression through the nucleotide binding oligomerization domain containing 2 (NOD2)/nuclear factor (NF)‑κB pathway. The data also demonstrated that TRIM22 functions as an inhibitor of EnC tumor xenograft growth in vivo. Overall, the findings of the present study define a novel regulatory role for TRIM22 in EnC progression. Moreover, TRIM22 may serve as an important prognostic predictor for EnC.

Related Articles

Journal Cover

May 2020
Volume 56 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Zhang, L., Zhang, B., Wei, M., Xu, Z., Kong, W., Deng, K. ... Yan, L. (2020). TRIM22 inhibits endometrial cancer progression through the NOD2/NF‑κB signaling pathway and confers a favorable prognosis. International Journal of Oncology, 56, 1225-1239. https://doi.org/10.3892/ijo.2020.5004
MLA
Zhang, L., Zhang, B., Wei, M., Xu, Z., Kong, W., Deng, K., Xu, X., Zhang, L., Ζhao, X., Yan, L."TRIM22 inhibits endometrial cancer progression through the NOD2/NF‑κB signaling pathway and confers a favorable prognosis". International Journal of Oncology 56.5 (2020): 1225-1239.
Chicago
Zhang, L., Zhang, B., Wei, M., Xu, Z., Kong, W., Deng, K., Xu, X., Zhang, L., Ζhao, X., Yan, L."TRIM22 inhibits endometrial cancer progression through the NOD2/NF‑κB signaling pathway and confers a favorable prognosis". International Journal of Oncology 56, no. 5 (2020): 1225-1239. https://doi.org/10.3892/ijo.2020.5004